T-Score of -2.4: Diagnosis and Treatment
A T-score of -2.4 indicates osteopenia (low bone mass), not osteoporosis, but you should strongly consider pharmacologic treatment if additional risk factors are present or if fracture risk assessment indicates high risk.
What This T-Score Means
A T-score of -2.4 means your bone mineral density is 2.4 standard deviations below the young adult mean 1. This falls into the osteopenia range (between -1.0 and -2.5), which is not diagnostic of osteoporosis by BMD criteria alone. The osteoporosis threshold is T-score ≤ -2.5 1, 2, 1.
However, this classification alone does not determine treatment—fracture risk assessment is essential because most fractures actually occur in people with osteopenia, not osteoporosis 3.
Treatment Decision Algorithm
Step 1: Calculate Your 10-Year Fracture Risk Using FRAX
Use the FRAX tool (available online) which incorporates:
- Age
- Sex
- BMI
- Prior fragility fracture
- Parent hip fracture history
- Current smoking
- Glucocorticoid use
- Rheumatoid arthritis
- Secondary osteoporosis causes
- Alcohol intake (≥3 drinks/day)
- Your femoral neck BMD 1, 2, 1
Step 2: Apply Treatment Thresholds
Pharmacologic therapy is strongly recommended if 1, 2, 1:
- 10-year probability of major osteoporotic fracture ≥20%, OR
- 10-year probability of hip fracture ≥3%
These are U.S. thresholds (Grade A recommendation) 2, 1.
Step 3: Consider Additional High-Risk Features
Treat regardless of FRAX score if you have 1:
- History of fragility fracture (especially hip or spine)
- Recent fracture (within past 12 months)
- Multiple fractures
- Fractures while on osteoporosis therapy
- Long-term glucocorticoid use
- Very high fall risk or history of injurious falls
Recommended Treatment Options
If Treatment Is Indicated:
First-line therapy (high fracture risk) 1:
- Oral bisphosphonates: Alendronate 70 mg weekly OR Risedronate 35 mg weekly
- Alternative first-line: Denosumab 60 mg subcutaneously every 6 months OR Zoledronic acid 5 mg IV annually
These agents reduce hip, vertebral, and nonvertebral fractures (Grade A evidence) 1.
For very high fracture risk (FRAX major fracture >30% or hip fracture >4.5%, or T-score <-3.0) 1:
- Consider anabolic agents first: Teriparatide, Abaloparatide, or Romosozumab
- Then transition to antiresorptive therapy
If Treatment Is NOT Indicated:
Lifestyle interventions (Grade A-B recommendations) 1, 2, 1:
- Calcium: 1,000-1,200 mg daily (dietary plus supplements if needed)
- Vitamin D: 600-800 IU daily; target serum level ≥20 ng/mL 4
- Weight-bearing and resistance exercise (Grade A)
- Smoking cessation (Grade B)
- Limit alcohol to ≤2 units/day (Grade B)
- Fall prevention strategies (Grade B)
Critical Caveats
Common pitfall: The 2017 ACP guideline 5 takes a more conservative approach, recommending treatment primarily for women ≥65 years with osteoporosis (T-score ≤-2.5) and suggesting individualized decisions for osteopenic women. However, the 2020 AACE/ACE guidelines 1, 2, 1 provide more aggressive, evidence-based thresholds using FRAX, which better captures fracture risk and is the approach I recommend prioritizing for reducing morbidity and mortality.
Important: Most fractures occur in people with osteopenia because this population is much larger than those with osteoporosis 3. A T-score of -2.4 with high FRAX scores or risk factors absolutely warrants treatment.
Monitoring: If you start treatment, do NOT routinely repeat BMD during the first 5 years of therapy 5. Treatment decisions should be based on fracture risk, not BMD changes.
Denosumab warning: If you start denosumab and later discontinue it, there is rebound bone loss and increased vertebral fracture risk—transition to bisphosphonate therapy is essential 6.